Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Strengthening capabilities in Peptide Therapeutics and CDMO services
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
Subscribe To Our Newsletter & Stay Updated
